Sec. 2410. Study on incentives for domestic production of generic medicines
220 words·~1 min read·
/bill/117/hr/2617/unknown/section-2410A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Secretary of Health and Human Services (referred to in this section as the Secretary ), acting through the Assistant Secretary for Planning and Evaluation of the Department of Health and Human Services shall— conduct a study on the feasibility, including related to sustainment, and potential effectiveness, and utility of providing incentives for increased domestic production and capacity of specified generic medicines and their active pharmaceutical ingredients, which may include through applicable nonprofit or for-profit private entities; and not later than 1 year after the date of enactment of this Act, submit a report on such study to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives.
In this section, the term specified generic medicine means a generic drug approved under section 505(j) of the Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j) ) that is — used to prevent, mitigate, or treat a serious or life-threatening disease or condition, or used in a common procedure that could be life-threatening without such medicine; an antibiotic or antifungal used to treat a serious or life threatening infectious disease; critical to the public health during a public health emergency; or life-supporting, life-sustaining, or intended for use in the prevention or treatment of a debilitating disease or condition.
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Sec. 2410
Study on incentives for domestic production of generic medicines
Cites 1Cited by 0 across 0 sources